<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Lexaria Bioscience Corp (NASDAQ: LEXX) has announced that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results. The study demonstrated that DehydraTECH enabled colchicine, one of the products tested by Lexaria with known SARS-CoV-2 antiviral properties, benefited from its proprietary formulation and processing, resulting in increased delivery.
...read full article on Benzinga
